Menu Search
Equities

Ultimovacs ASA

ULTI:OSL

Ultimovacs ASA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)1.83
  • Today's Change0.062 / 3.50%
  • Shares traded756.09k
  • 1 Year change-97.67%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform0
Hold0
Sell0
Strong Sell1

Share price forecast in NOK

The 2 analysts offering 12 month price targets for Ultimovacs ASA have a median target of 5.75, with a high estimate of 9.00 and a low estimate of 2.50. The median estimate represents a 213.86% increase from the last price of 1.83.
High391.3%9.00
Med213.9%5.75
Low36.5%2.50

Earnings history & estimates in NOK

Ultimovacs ASA reported annual 2023 losses of -5.50 per share on Feb 14, 2024.
Average growth rate-20.99%
More ▼

Revenue history & estimates in NOK

Ultimovacs ASA did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.